Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) announced that CEO Bobak Azamian will speak at the Virtual Jefferies London Healthcare Conference. The fireside chat will be available on-demand from November 18 at 8:00 AM GT through November 19. Additionally, Tarsus will host virtual one-on-one meetings on November 19. Interested parties can schedule a meeting through their Jefferies representative. For further details, including potential changes to the presentation schedule, visit www.tarsusrx.com. Tarsus is advancing its pipeline in eye care and other therapeutic areas.

IRVINE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus will participate in a fireside chat at the Virtual Jefferies London Healthcare Conference.

Fireside Chat Presentation Details

• The fireside chat will be available on-demand beginning Thursday, November 18^th at 8:00am GT / 12:00am PT through Friday, November 19^th
  

Management will also host virtual one-on-one meetings on November 19, 2021. For additional information or to schedule a meeting, please contact your Jefferies representative.

The above listed dates are subject to change. Details on the presentation time or changes to the presentation date can be found on the Company's website. Please check www.tarsusrx.com for the latest information.

A live webcast of the presentation will also be available on the events section of the Tarsus website. The replay will be available within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.

Contacts:
Media Contact:
SuJin Oh
Shop PR
(917) 841-5213
sujin@shop-pr.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com 

FAQ

When will Tarsus Pharmaceuticals participate in the Jefferies London Healthcare Conference?

Tarsus Pharmaceuticals will participate in the Jefferies London Healthcare Conference on November 18, 2021, with a fireside chat available on-demand.

What is the main focus of Tarsus Pharmaceuticals as mentioned in the press release?

Tarsus Pharmaceuticals focuses on meeting unmet medical needs, particularly in eye care and other therapeutic areas, using proven science and new technology.

How can I access the Tarsus Pharmaceuticals fireside chat?

The fireside chat will be available on-demand starting November 18 at 8:00 AM GT, accessible through the Tarsus website.

What is the date for Tarsus Pharmaceuticals' virtual one-on-one meetings?

The virtual one-on-one meetings hosted by Tarsus Pharmaceuticals are scheduled for November 19, 2021.

What investigational medicines is Tarsus Pharmaceuticals currently studying?

Tarsus is studying two investigational medicines: TP-03 for Demodex blepharitis and Meibomian Gland Disease and TP-05 for Lyme disease prevention.